Drugs · Entity Annotation Prototype (beta)

7articles mentioning drugs

13drug mentions

1distinct drugs extracted

0%of mentions human-reviewed

Active filtersEntity: bDMARDs ×

bDMARDs

This drug is selected. Its supporting articles are shown below.

bDMARDs7

Articles mentioning bDMARDs

7 articles · page 1 of 1

Effect of a smart temperature logger on correctly storing biological disease-modifying antirheumatic drugs at home: a pre-post study

ejhpharm · abstract · 2025-10-24 · 5 matching annotations

93.7%

bDMARDs Biological disease-modifying antirheumatic drugs rheumatic diseases eHealth interventions

…Objectives Biological disease-modifying antirheumatic drugs (bDMARDs) require specific storage temperatures, but are frequently stor…

Remote personalised exercise in axial spondyloarthritis: the SPARK trial – protocol for a 6-month randomised controlled trial

bmjopen · abstract · 2026-03-30 · 3 matching annotations

90.9%

bDMARDs exercise axial spondyloarthritis (SpA)SpA Ankylosing Spondylitis Disease Activity Score

…12 in each group. Secondary outcomes include use of medication (bDMARDs and non-steroidal anti-inflammatory drugs (NSAIDs)), cardioresp…

Sex differences in long-term functional deterioration and permanent disability in spondyloarthritis: a 17-year follow-up from the REGISPON-3 study

rmdopen · abstract · 2026-07-15 · 1 matching annotations

85.1%

bDMARDs bDMARD SpA spondyloarthritis (SpA)REGISPON-3

…ciation between biologic disease-modifying antirheumatic drugs (bDMARDs) exposure and functional change in a sex-dependent manner.Metho…

EULAR-OMERACT consensus-based scoring system for synovitis 10 years later: a validated tool for routine care and clinical trials

rmdopen · abstract · 2026-04-01 · 1 matching annotations

88.9%

bDMARD bDMARDs Disease Activity Score 28 synovitis arthritis European Alliance of Associations for Rheumatology EULAR EULAR-OMERACT OMERACT

…e validity for biological disease-modifying antirheumatic drug (bDMARD) discontinuation and for flares while tapering bDMARDs. In addi…

Effect of targeted therapies on pulmonary function in rheumatoid arthritis-associated interstitial lung disease: a systematic review and meta-analysis

rmdopen · abstract · 2026-03-19 · 1 matching annotations

80.4%

tocilizumab rituximab abatacept tsDMARDs bDMARDs rheumatoid arthritis PubMed RA-ILD Interstitial lung disease (ILD)Cochrane+1 more

…inhibitors (4), tumour necrosis factor (TNF) inhibitors (1) and tocilizumab (1). Pooled analysis showed no significant overall change in FV…

PeRsonalIsed MEdicine in Rheumatoid Arthritis (PRIMERA) trial: a multicentre, open-label, randomised controlled trial comparing routine care with a tailor-made approach

bmjopen · abstract · 2025-12-18 · 1 matching annotations

77.8%

methotrexate hydroxychloroquine GCs tsDMARDs bDMARDs Rheumatoid arthritis RA Erasmus MC Medical Ethics Review Committee personalised medicine

…nd autoantibody-negative RA starting with hydroxychloroquine or methotrexate together with a single intramuscular dose of GCs, respectively.…

Seventeen-year reassessment of diagnostic transitions, biologic therapy initiation and mortality in spondyloarthritis: results from the REGISPON-3 study

rmdopen · abstract · 2025-10-05 · 1 matching annotations

93.1%

bDMARDs psoriatic arthritis REGISPON-3 SpA cancer Spondylitis Spondyloarthritis REGISPONSER

…nge. The use of biologic disease-modifying antirheumatic drugs (bDMARDs) increased from 13.1% to 52.1%. However, the median time to fir…